HC Wainwright Forecasts Genmab A/S FY2027 Earnings

Key Points

• HC Wainwright maintained a Buy rating and a $40 price target for Genmab, forecasting FY2027 earnings of $1.48 per share versus the current-year consensus estimate of $1.17.
• Analyst sentiment is broadly positive: Genmab has a consensus rating of Moderate Buy and an average price target of $39.50, with several firms recently raising targets or upgrading the stock.
• Genmab exceeded quarterly expectations, reporting $0.54 in EPS versus $0.37 expected and $1.16 billion in revenue versus $1.12 billion forecast. Institutional investors also increased holdings, while the stock opened at $32.65.

Genmab A/S Sponsored ADR (NASDAQ:GMAB - Free Report) - Equities research analysts at HC Wainwright issued their FY2027 earnings estimates for Genmab A/S in a research note issued to investors on Monday, September 14th. HC Wainwright analyst R. Selvaraju expects that the company will post earnings of $1.48 per share for the year. HC Wainwright currently has a "Buy" rating and a $40.00 target price on the stock. The consensus estimate for Genmab A/S's current full-year earnings is $1.17 per share.

A number of other analysts also recently weighed in on the company. Guggenheim lifted their price target on Genmab A/S from $40.00 to $42.00 and gave the company a "buy" rating in a research note on Friday, August 7th. Weiss Ratings raised Genmab A/S from a "hold (c)" rating to a "hold (c+)" rating in a report on Tuesday, September 1st. New Street Research set a $43.00 target price on shares of Genmab A/S in a research report on Wednesday, July 22nd. Truist Financial assumed coverage on shares of Genmab A/S in a research note on Wednesday, May 27th. They set a "buy" rating and a $40.00 price target on the stock. Finally, TD Cowen upgraded shares of Genmab A/S from a "hold" rating to a "buy" rating and raised their price objective for the company from $32.00 to $43.00 in a research note on Wednesday, July 22nd. One investment analyst has rated the stock with a Strong Buy rating, nine have issued a Buy rating and three have assigned a Hold rating to the stock. According to data from MarketBeat, Genmab A/S presently has a consensus rating of "Moderate Buy" and an average price target of $39.50.

Genmab A/S Stock Performance

NASDAQ GMAB opened at $32.65 on Tuesday. The stock has a market capitalization of $20.37 billion, a price-to-earnings ratio of 25.71, a PEG ratio of 1.83 and a beta of 0.84. The business's 50 day moving average is $31.09 and its two-hundred day moving average is $28.28. Genmab A/S has a 12-month low of $23.62 and a 12-month high of $35.43. The company has a current ratio of 2.46, a quick ratio of 2.44 and a debt-to-equity ratio of 0.81.

Genmab A/S (NASDAQ:GMAB - Get Free Report) last posted its quarterly earnings results on Thursday, August 6th. The company reported $0.54 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.37 by $0.17. Genmab A/S had a net margin of 19.08% and a return on equity of 14.89%. The firm had revenue of $1.16 billion during the quarter, compared to analysts' expectations of $1.12 billion.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in the company. Arrowstreet Capital Limited Partnership boosted its position in Genmab A/S by 36.6% during the fourth quarter. Arrowstreet Capital Limited Partnership now owns 4,978,058 shares of the company's stock worth $153,324,000 after acquiring an additional 1,334,919 shares during the last quarter. Renaissance Technologies LLC lifted its holdings in shares of Genmab A/S by 26.4% during the 1st quarter. Renaissance Technologies LLC now owns 4,414,550 shares of the company's stock worth $118,442,000 after acquiring an additional 921,700 shares during the period. First Trust Advisors LP boosted its position in shares of Genmab A/S by 84.3% in the first quarter. First Trust Advisors LP now owns 2,461,342 shares of the company's stock worth $66,038,000 after acquiring an additional 1,126,069 shares during the last quarter. Cibc World Market Inc. boosted its position in shares of Genmab A/S by 31.2% in the fourth quarter. Cibc World Market Inc. now owns 367,282 shares of the company's stock worth $11,312,000 after acquiring an additional 87,350 shares during the last quarter. Finally, Quantinno Capital Management LP grew its holdings in Genmab A/S by 14.4% in the first quarter. Quantinno Capital Management LP now owns 282,498 shares of the company's stock valued at $7,579,000 after purchasing an additional 35,588 shares during the period. Institutional investors and hedge funds own 7.07% of the company's stock.

About Genmab A/S

Genmab A/S is a biotechnology company headquartered in Copenhagen, Denmark, focused on discovering, developing and commercializing differentiated antibody-based medicines. The company's research platforms include technologies designed to create human antibodies and bispecific antibodies that engage the immune system to target cancer and other serious diseases.

Genmab's products and partnered medicines include DARZALEX (daratumumab) for multiple myeloma, developed with Johnson & Johnson; Kesimpta (ofatumumab) for multiple sclerosis, developed with Novartis; and Tivdak (tisotumab vedotin) for cervical cancer, developed with Pfizer.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.